ABCC5 (ATP Binding Cassette Subfamily C Member 5)

UGT1A1*6 and ABCC2 -24C > T variants emerge as potential predictors of irinotecan-induced neutropenia, while UGT1A1*6 and SLCO1B1 521T > C may serve as markers of prolonged PFS in Thai patients. Validation through larger prospective studies is essential to confirm and refine these genetic associations.

SIGNIFICANCE STATEMENT: This study provides evidence that BRG1 inhibition with PFI3 and degradation of SMARCA4 mRNA substantially declines lysosomal drug sequestration and potentiate drug toxicity. Therefore, BRG1 targeting can be considered as candidate for combinatorial anticancer therapy with some standard chemotherapy drugs.

HA-mEXO carrying ZNF516 suppress ABCC5 expression, thereby enhancing the sensitivity of A549 and PC-9 LAUD drug-resistant cells to PMX.

Analysis of The Cancer Genome Atlas (TCGA) and The Genotype-Tissue Expression (GTEx) databases confirmed a likely role of HIF1A-BRG1-p300 overexpression in the taxanes resistance of cancer patients and the possible biomarker function of this protein in cancer responses to chemotherapy. Therefore, the complex comprising BRG1-EP300-HIF1A can be considered for further clinical investigation and planning for patient therapy.

However, this review emphasises caution in targeting ABCC5 for cancer therapy due to its underappreciated physiological function(s), particularly in the brain and male reproductive system. Understanding ABCC5's substrate specificity, regulatory mechanisms, and functional redundancy with its paralog ABCC12 remains critical for successful therapeutic strategies in humans.

Experimental validation included qRT-PCR, Western blot, migration assays, and drug response studies using the ABCC5 inhibitor zidovudine (ZDV)...Multi-omics analysis and experimental validation confirmed that ABCC5 drives HCC progression by participating in immune microenvironment reprogramming, affecting cell cycle progression, and regulating the p53 signaling pathway. The research not only identified potential diagnostic markers and therapeutic targets, but the established prognostic model also provides new insights for investigating HCC pathogenesis and clinical translation.

Further cost-effectiveness studies and ethnically diverse prediction models are needed to demonstrate the impact of pharmacogenomic testing on ACT prognosis and clinical decision-making prior to adoption. PROSPERO identifier CRD42024557946.

The results of this study endorse the possibility of performing a genetic screening before anticancer immunochemotherapy as a future tool for stratifying patients with an oncohematological profile and minimizing CV toxicity. However, further studies are needed to confirm the diagnostic and prognostic role of the above identified genetic variants.

Although GDF15 expression was decreased in CRPC cells, overexpression of GDF15 still facilitates CRPC cells migration and invasion in vitro. Our findings suggest that this novel FRGs signature and GDF15 could be robust biomarkers for predicting CRPC in clinical practice.

In summary, TPI ameliorates NAFLD by mitigating hepatic lipid accumulation both in vivo and in vitro, through inhibition of the KLF6/ABCC5 pathway.

The combined knockdown of ZNF516 reversed the antitumor benefits of mEXOs. HA-mEXOs-carrying ZNF516 enhance ZNF516 levels in LUAD/PMX cells and repress ABCC5, which in turn induces cell sensitivity to PMX and inhibits LUAD progression.

Given that ABCC5 is regulated by several pathways in a broad range of cancer types, it is a prospective target for cancer treatment. This review examined the expression, structure, function, and role of ABCC5 in various cancer types.